SCHEMBL18159035

SCHEMBL18159035

CC(CCCCNC(=O)CON)C(N)=O

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.38
KMT2A Q03164 3/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
ALB P02768 1/20 0.33
DPP7 Q9UHL4 2/20 0.33
CASP2 P42575 1/20 0.33
GNAI3 P08754 1/20 0.32
GNAO1 P09471 1/20 0.32
GNAI1 P63096 1/20 0.32
TSHR P16473 1/20 0.32
ITGB3 P05106 2/20 0.32
ITGA2B P08514 2/20 0.32
LMNA P02545 1/20 0.31
HPGD P15428 1/20 0.31
TP53 P04637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20034810 0.85 FAAH (0.41) FAAHKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL254104 0.83 FAAH (0.44) FAAHKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL20034909 0.79 FAAH (0.37) FAAHKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL12064338 0.78 GLP1R (0.41) FAAHKMT2AMEN1ALB
SCHEMBL12743575 0.78 GLP1R (0.45) FAAHKMT2AMEN1DPP7CASP2
SCHEMBL14683490 0.78 MEN1 (0.44) FAAHKMT2AMEN1TSHR
SCHEMBL12147600 0.78 GLP1R (0.48) KMT2AMEN1ALDH1A1ALBCASP2
SCHEMBL14683542 0.78 GLP1R (0.43) FAAHKMT2AMEN1ALDH1A1TSHR
SCHEMBL12743587 0.78 GLP1R (0.45) FAAHKMT2AMEN1DPP7CASP2
SCHEMBL24899909 0.78 KDM4E (0.56) ALDH1A1ALBDPP7GNAI3GNAO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160303263-A1 RADIOTRACER COMPOSITIONS AND METHODS GE HEALTHCARE LIMITED (GB) 2016-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160303263-A1 RADIOTRACER COMPOSITIONS AND METHODS MET, METTL14, MEN1 FAAH 1581/4885KMT2A 2751/4885MEN1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.